01:37 PM EDT, 09/03/2025 (MT Newswires) -- Immunovant ( IMVT ) said Wednesday its proof-of-concept study for batoclimab showed potential for treating patients with uncontrolled Graves' disease, an autoimmune disorder.

Six-month off-treatment data in uncontrolled Graves' disease patients treated with batoclimab for 24 weeks showed that around 80% of the patients demonstrated response, resulting in normal thyroid function, the company said.

Of the responders to the therapy, around 50% achieved anti-thyroid drug free remission six months after the end of the treatment, Immunovant ( IMVT ) said.

The company said it is currently enrolling for two potentially registrational trials for its lead compound IMVT-1402 in Graves' disease, with topline readouts expected in 2027.

Shares of Immunovant ( IMVT ) were up 10% in recent trading Wednesday.

Price: 15.75, Change: +0.67, Percent Change: +4.48